Aliases & Classifications for Cytomegalovirus Infection

MalaCards integrated aliases for Cytomegalovirus Infection:

Name: Cytomegalovirus Infection 51 3
Cytomegalovirus Infections 41 69

Summaries for Cytomegalovirus Infection

NINDS : 51 Cytomegalovirus (CMV) is a virus found throughout the world that infects between 50 to 80 percent of all adults in the United States by the age of 40.  CMV is in the same family of viruses that causes cold sores (herpes simplex virus), infectious mononucleosis (Epstein-Barr virus), and chickenpox/shingles (varicella zoster virus).    Most people who acquire CVM as children or adults display no signs of illness or have mild symptoms such as fever, fatigue, or tender lymph nodes.  People with a compromised immune system may have more severe forms of infection involving the nervous system. A hallmark of CMV infection is that the virus cycles through periods of dormancy and active infection during the life of the individual  Infected persons of any age periodically shed the virus in their body fluids, such as saliva, urine, blood, tears, semen, or breast milk.  CMV is most commonly transmitted when infected body fluids come in contact with the mucous membranes of an uninfected person, but the virus can also pass from mother to fetus during pregnancy.  

MalaCards based summary : Cytomegalovirus Infection, also known as cytomegalovirus infections, is related to ulcerative colitis and cytomegalovirus retinitis, and has symptoms including fever and pruritus. An important gene associated with Cytomegalovirus Infection is RAG1 (Recombination Activating 1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Basiliximab and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include t cells, kidney and eye, and related phenotypes are cardiovascular system and hematopoietic system

MedlinePlus : 41 cytomegalovirus (cmv) is a virus found around the world. it is related to the viruses that cause chickenpox and infectious mononucleosis (mono). between 50 percent and 80 percent of adults in the united states have had a cmv infection by age 40. once cmv is in a person's body, it stays there for life. cmv is spread through close contact with body fluids. most people with cmv don't get sick and don't know that they've been infected. but infection with the virus can be serious in babies and people with weak immune systems. if a woman gets cmv when she is pregnant, she can pass it on to her baby. usually the babies do not have health problems. but some babies can develop lifelong disabilities. a blood test can tell whether a person has ever been infected with cmv. most people with cmv don't need treatment. if you have a weakened immune system, your doctor may prescribe antiviral medicine. good hygiene, including proper hand washing, may help prevent infections. centers for disease control and prevention

CDC : 3 Cytomegalovirus (pronounced sy-toe-MEG-a-low-vy-rus), or CMV, is a common virus that infects people of all ages. Over half of adults by age 40 have been infected with CMV. Once CMV is in a person’s body, it stays there for life and can reactivate. Most people infected with CMV show no signs or symptoms. However, CMV infection can cause serious health problems for people with weakened immune systems, as well as babies infected with the virus before they are born (congenital CMV).

Related Diseases for Cytomegalovirus Infection

Diseases related to Cytomegalovirus Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 534)
id Related Disease Score Top Affiliating Genes
1 ulcerative colitis 30.6 IL10 IL6 TNF
2 cytomegalovirus retinitis 30.2 CXCL8 ICAM1
3 toxoplasmosis 30.1 IL6 TNF
4 primary biliary cirrhosis 29.9 IL10 IL6 TNF
5 chronic graft versus host disease 29.8 IFNG IL10 SELE
6 autoimmune hepatitis 29.8 ICAM1 SELE TNF VCAM1
7 lymphoma 29.7 IFNG IL10 IL6 TNF
8 angina pectoris 29.5 IL6 SELE VCAM1
9 epidermolysis bullosa acquisita 29.5 CCL5 IFNG IL10
10 cryoglobulinemia 29.1 CXCL8 IL10 IL6
11 choroiditis 29.1 CXCL8 IL10 IL6 TNF
12 legionellosis 29.0 CXCL8 IFNG IL6 TNF
13 atherosclerosis 28.8 CXCL8 IFNG IL10 IL6 TNF
14 hemophagocytic lymphohistiocytosis 28.7 IFNG IL10 IL6 KIR3DL1 TNF
15 pulmonary embolism 28.5 CXCL8 IFNG IL10 IL6 TNF
16 hepatitis b 28.5 CXCL8 IFNG IL10 IL2RA TNF
17 churg-strauss syndrome 28.5 CXCL8 ICAM1 IFNG IL10 SELE TNF
18 neonatal jaundice 28.0 CCL5 ICAM1 IFNG IL10 IL6 TNF
19 myelitis 27.6 CCL5 IFNG IL10 IL2RA IL6
20 rheumatoid arthritis 27.4 CCL5 CXCL8 ICAM1 IFNG IL10 IL6
21 systemic lupus erythematosus 26.4 CCL5 ICAM1 IFNG IL10 IL2RA IL6
22 asthma 24.9 CCL5 CXCL8 HLA-G ICAM1 IFNG IL10
23 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 12.3
24 neurological consequences of cytomegalovirus infection 11.9
25 idiopathic disseminated cytomegalovirus infection 11.9
26 fetal cytomegalovirus syndrome 11.3
27 cytomegalic inclusion disease 11.1
28 pure autonomic failure 10.8 IL10 TNF
29 congenital cytomegalovirus 10.8
30 acute ackee fruit intoxication 10.8 IL10 TNF
31 immunodeficiency 14 10.8
32 aids - neurological complications 10.8
33 hodgkin's lymphoma, nodular sclerosis 10.7 ICAM1 SELE
34 multiple familial trichoepithelioma 10.7 IL10 TNF
35 sternal cleft 10.6 IFNG TNF
36 lagophthalmos 10.6 IL10 TNF
37 type 1 papillary adenoma of the kidney 10.6 IL10 TNF
38 lymphomatous thyroiditis 10.6 ICAM1 SELE VCAM1
39 dermatomycosis 10.6 ICAM1 SELE TNF
40 marginal corneal ulcer 10.6 ICAM1 SELE VCAM1
41 inferolateral myocardial infarct 10.6 ICAM1 SELE VCAM1
42 dracunculiasis 10.6 ICAM1 SELE TNF
43 congenital diaphragmatic hernia 10.6 CXCL8 ICAM1
44 phlegmonous dacryocystitis 10.6 ICAM1 SELE VCAM1
45 craniopharyngioma 10.6 ICAM1 SELE VCAM1
46 autoimmune polyglandular syndrome type 3 10.6 IFNG TNF VCAM1
47 tick-borne encephalitis 10.6 ICAM1 SELE TNF
48 heart lymphoma 10.5 ICAM1 VCAM1
49 pericardium disease 10.5 IL10 TNF VCAM1
50 aortic arch interruption 10.5 IL6 TNF

Comorbidity relations with Cytomegalovirus Infection via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Cytomegalovirus Infection:



Diseases related to Cytomegalovirus Infection

Symptoms & Phenotypes for Cytomegalovirus Infection

UMLS symptoms related to Cytomegalovirus Infection:


fever, pruritus

MGI Mouse Phenotypes related to Cytomegalovirus Infection:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.24 GJB2 ICAM1 IFNG IL10 IL6 MTOR
2 hematopoietic system MP:0005397 10.23 CCL5 HLA-G ICAM1 IFNG IL10 IL2RA
3 cellular MP:0005384 10.22 GJB2 ICAM1 IFNG IL10 IL6 MTOR
4 growth/size/body region MP:0005378 10.22 GJB2 ICAM1 IFNG IL10 IL2RA IL6
5 immune system MP:0005387 10.22 CCL5 GJB2 HLA-G ICAM1 IFNG IL10
6 homeostasis/metabolism MP:0005376 10.21 HLA-G ICAM1 IFNG GJB2 IL10 IL2RA
7 endocrine/exocrine gland MP:0005379 10.1 ICAM1 IFNG IL10 IL2RA IL6 MTOR
8 mortality/aging MP:0010768 10.06 GJB2 ICAM1 IFNG IL10 IL2RA IL6
9 digestive/alimentary MP:0005381 10.05 ICAM1 IFNG IL10 IL2RA IL6 RAG1
10 integument MP:0010771 9.97 SELE TNF GJB2 ICAM1 IFNG IL10
11 neoplasm MP:0002006 9.73 IL6 RAG1 ICAM1 IFNG IL10 TNF
12 no phenotypic analysis MP:0003012 9.7 GJB2 IFNG IL10 KLRB1 MTOR TNF
13 respiratory system MP:0005388 9.56 IFNG IL10 IL2RA IL6 MTOR RAG1
14 vision/eye MP:0005391 9.28 GJB2 ICAM1 IFNG IL10 IL2RA IL6

Drugs & Therapeutics for Cytomegalovirus Infection

Drugs for Cytomegalovirus Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 227)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
2
Everolimus Approved Phase 4,Phase 3,Phase 2 159351-69-6 6442177
3
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 22916-47-8 4189
5
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
6
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
8
Prednisone Approved, Vet_approved Phase 4,Phase 3 53-03-2 5865
9
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2 53123-88-9 5284616 6436030 46835353
10
Tacrolimus Approved, Investigational Phase 4,Phase 3 104987-11-3 445643 439492
11
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
12
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 82410-32-0 3454
13
Valganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 175865-60-8 64147
14
Foscarnet Approved Phase 4,Phase 3,Phase 2,Phase 1 63585-09-1, 4428-95-9 3415
15
Pancrelipase Approved Phase 4 53608-75-6
16
Cidofovir Approved Phase 4,Phase 3,Phase 2,Phase 1 113852-37-2 60613
17
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
18
Benzocaine Approved Phase 4 1994-09-7, 94-09-7 2337
19
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754 657311
20
Magnesium Sulfate Approved, Vet_approved Phase 4 7487-88-9 24083
21
Infliximab Approved Phase 4 170277-31-3
22
Probenecid Approved Phase 4,Phase 2,Phase 1 57-66-9 4911
23
Azathioprine Approved Phase 4 446-86-6 2265
24 tannic acid Approved, Nutraceutical Phase 4
25
Phosphonoacetic Acid Experimental Phase 4,Phase 3,Phase 2,Phase 1 4408-78-0 546
26 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
27 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
28 Antiemetics Phase 4
29 Antifungal Agents Phase 4,Phase 3,Phase 2
30 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Anti-Inflammatory Agents Phase 4,Phase 3
32 Antirheumatic Agents Phase 4,Phase 2,Phase 1
33 Autonomic Agents Phase 4
34 Calcineurin Inhibitors Phase 4,Phase 3
35 Cyclosporins Phase 4,Phase 3,Phase 2
36 Dermatologic Agents Phase 4
37 Gastrointestinal Agents Phase 4,Phase 1
38 glucocorticoids Phase 4,Phase 3
39 Hormone Antagonists Phase 4,Phase 3,Phase 2
40 Hormones Phase 4,Phase 3,Phase 2
41 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
42 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
43 Methylprednisolone acetate Phase 4,Phase 3
44 Methylprednisolone Hemisuccinate Phase 4,Phase 3
45 Neuroprotective Agents Phase 4
46 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1
47 Prednisolone acetate Phase 4,Phase 3
48 Prednisolone hemisuccinate Phase 4,Phase 3
49 Prednisolone phosphate Phase 4,Phase 3
50 Protective Agents Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 360)

id Name Status NCT ID Phase Drugs
1 Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporineversus an Immunosuppressive Regimen With Mycophenolic Acid and Unknown status NCT02328963 Phase 4 Everolimus;mycophenolic acid
2 Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients Unknown status NCT01927588 Phase 4 Everolimus+Tacrolimus+Prednisone;Mycophenolate+Tacrolimus+Prednisone
3 Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant Unknown status NCT02084446 Phase 4 Everolimus;Very Low Tacrolimus;Low Tacrolimus;Steroids;Thymoglobulin;Sodium Mycophenolate
4 Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients Unknown status NCT00364052 Phase 4 oral Valganciclovir vs oral Ganciclovir
5 Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection Completed NCT01509404 Phase 4 Valganciclovir;Valganciclovir
6 Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients Completed NCT00730769 Phase 4 Single arm (ganciclovir and valganciclovir)
7 The Influence of Chronic CMV Infection on Influenza Vaccine Responses Completed NCT02134184 Phase 4
8 Cell Mediated Immunity and the Prediction of CMV Infection In Solid Organ Transplant Recipients Completed NCT00436384 Phase 4
9 Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV) Completed NCT00947141 Phase 4 ganciclovir (start when CMV PCR >200copies / ml x2);Stop treatment when 2 levels CMV PCR <3,000 copies / ml
10 Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients Completed NCT00034385 Phase 4 Valganciclovir
11 Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients Completed NCT02683291 Phase 4 sirolimus;tacrolimus;mycophenolate;Prednisone;Basiliximab;Thymoglobulin
12 A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients Completed NCT01376804 Phase 4 valganciclovir [Valcyte]
13 Influence of Persistent CMV-infection on Immune Senescence Completed NCT00461695 Phase 4
14 VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients Completed NCT00431353 Phase 4 Ganciclovir;valganciclovir [Valcyte]
15 Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients Completed NCT00373165 Phase 4 Ganciclovir
16 Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate Completed NCT01354301 Phase 4 Thymoglobulin;Everolimus;Basiliximabe;mycophenolate sodium;Tacrolimus;Tacrolimus;Tacrolimus
17 Valganciclovir to Reduce T Cell Activation in HIV Infection Completed NCT00264290 Phase 4 Valganciclovir;Placebo
18 Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study Completed NCT00002146 Phase 4 Magnesium sulfate;Foscarnet sodium
19 Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients. Completed NCT01446445 Phase 4 Ganciclovir/ Valganciclovir according to SPC;Ganciclovir/ Valganciclovir according to PK model
20 Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration Completed NCT01866397 Phase 4
21 Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis Completed NCT00542152 Phase 4 CYCLOSPORINE VS INFLIXIMAB
22 In Utero Treatment of Cytomegalovirus congénitale Infection With Valacyclovir Completed NCT01651585 Phase 4 Valacyclovir arrow
23 Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients Completed NCT00299221 Phase 4 Tacrolimus;combination therapy
24 A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium) Completed NCT00002125 Phase 4 Foscarnet sodium
25 Everolimus in de Novo Heart Transplant Recipients Completed NCT01017029 Phase 4 Everolimus;Mycophenolate mofetil + Everolimus
26 Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis Completed NCT00000894 Phase 4 Cidofovir;Probenecid;Ganciclovir
27 Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen Completed NCT00170820 Phase 4 Everolimus
28 Individually Adapted Immunosuppression in de Novo Renal Transplantation Based on Immune Function Monitoring: a Prospective Randomised Study Completed NCT00895206 Phase 4 individual adapted immunosuppression;golden standard therapy
29 Organ Transplant Infection Prevention and Detection Project Completed NCT00177801 Phase 4
30 Response of Older Adults to Influenza Vaccination With Regard to Cytomegalovirus (CMV) Status Completed NCT00442975 Phase 4
31 Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence Recruiting NCT02671318 Phase 4 Drug conversion to sirolimus;Maintenance of the current regimen
32 CMV-CTL for the Treatment of CMV Infection After HSCT Recruiting NCT03004261 Phase 4 Foscarnet;Ganciclovir
33 Prospective, Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection Based on Baseline hCMV Specific T-cell Response in Kidney Transplant Recruiting NCT02550639 Phase 4
34 Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Recruiting NCT02943057 Phase 4 2% guttae ganciclovir
35 PTH - Preemptive Treatment for Herpesviridae Recruiting NCT02152358 Phase 4 Aciclovir;Ganciclovir;Placebo
36 Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in Liver Transplant Recipients Active, not recruiting NCT01552369 Phase 4 Prophylaxis with Valganciclovir
37 In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir Terminated NCT01037712 Phase 4 Valacyclovir (ZELITREX);Placebo
38 Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy Terminated NCT00264368 Phase 4 intravenous (IV) ganciclovir
39 Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy Unknown status NCT00966836 Phase 3 Pre-emptive strategy with valganciclovir plus everolimus;Prophylaxis with valganciclovir plus mycophenolate;Prophylaxis with valganciclovir plus everolimus;Pre-emptive mycophenolate
40 Congenital Cytomegalovirus: Efficacy of Antiviral Treatment Unknown status NCT02005822 Phase 3 Valganciclovir
41 A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV) Unknown status NCT01157949 Phase 3 Thymoglobulin
42 Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection Unknown status NCT00017784 Phase 3 Valganciclovir
43 Anti-T-Lymphocyte Globulin (ATG) in Renal Transplantation of Kidneys With a Non-Heart-Beating (NHB) Donor Unknown status NCT00733733 Phase 3 ATG Fresenius
44 Efficacy Study of Human Cytomegalovirus (HCMV) Hyperimmune Globulin to Prevent Congenital HCMV Infection Completed NCT00881517 Phase 2, Phase 3 HCMV-specific hyperimmune globulin (Cytotect®);Isotonic solution of sodium chloride (placebo)
45 Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection Completed NCT00004278 Phase 3 ganciclovir
46 Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections Completed NCT00466817 Phase 3 Valganciclovir
47 Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation Completed NCT00016068 Phase 3 ganciclovir;valganciclovir
48 Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant Recipients Completed NCT00284687 Phase 3 Artesunate
49 MK-8228 (Letermovir) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001) Completed NCT02137772 Phase 3 MK-8228;Placebo
50 Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients Completed NCT00497796 Phase 3 maribavir;ganciclovir

Search NIH Clinical Center for Cytomegalovirus Infection

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Cytomegalovirus Infection

Anatomical Context for Cytomegalovirus Infection

MalaCards organs/tissues related to Cytomegalovirus Infection:

39
T Cells, Kidney, Eye, Liver, Testes, Breast, Lung

Publications for Cytomegalovirus Infection

Articles related to Cytomegalovirus Infection:

(show top 50) (show all 1390)
id Title Authors Year
1
Cellular responses to human cytomegalovirus infection: Induction of a mesenchymal-to-epithelial transition (MET) phenotype. ( 28874566 )
2017
2
Early Stochastic Dynamics in Human Cytomegalovirus Infection. ( 28839088 )
2017
3
Congenital cytomegalovirus infection in Central Germany: an underestimated risk. ( 28624987 )
2017
4
Knowledge of Human Cytomegalovirus Infection and Prevention in Pregnant Women: A Baseline, Operational Survey. ( 28831237 )
2017
5
Congenital Cytomegalovirus Infection: Prognostic Value of Maternal DNAemia at Amniocentesis. ( 27986666 )
2017
6
Enzyme-Linked Immunospot Assay as a Complementary Method to Assess and Monitor Cytomegalovirus Infection in Kidney Transplant Recipients on Pre-emptive Antiviral Therapy: A Single-Center Experience. ( 28923622 )
2017
7
Erdheim-Chester disease with unusual clinicopathological features complicated by DRESS syndrome, disseminated Cytomegalovirus infection and hemophagocytic lymphohistiocytosis. ( 28418177 )
2017
8
Juvenile myelomonocytic leukemia in an infant with congenital human immunodeficiency virus and cytomegalovirus infection. ( 28612348 )
2017
9
Pathogenesis of developmental anomalies of the central nervous system induced by congenital cytomegalovirus infection. ( 28074532 )
2017
10
Long-term Outcomes of Cochlear Implantation in Children With Congenital Cytomegalovirus Infection. ( 28604578 )
2017
11
Cytomegalovirus infection in a splenectomized with I^-thalassemia major: immunocompetent or immunosuppressed? ( 28680595 )
2017
12
Cutaneous Cytomegalovirus Infection in an Immunocompetent Patient: Innocent Bystander or Culprit? ( 28937438 )
2017
13
Human herpesvirus-8 and human cytomegalovirus infections in Bowen's disease: Is there any association? ( 28366922 )
2017
14
Hearing and neurodevelopmental outcomes for children with asymptomatic congenital cytomegalovirus infection: A systematic review. ( 28876493 )
2017
15
Massive splenomegaly due to concurrent primary Epstein-Barr virus and cytomegalovirus infection in a patient on adalimumab. ( 28864556 )
2017
16
Preexisting antibodies can protect against congenital cytomegalovirus infection in monkeys. ( 28679960 )
2017
17
Diagnosis of Cytomegalovirus Infection during Exacerbation of Ulcerative Colitis. ( 28848127 )
2017
18
Sensorineural Hearing Loss in a Patient Affected by Congenital Cytomegalovirus Infection: Is It Useful to Identify Comorbid Pathologies? ( 28794912 )
2017
19
Congenital Cytomegalovirus Infection after a Multiple-Birth Pregnancy. ( 28763424 )
2017
20
Infliximab as treatment of severe enteropathy in a patient with common variable immunodeficiency and cytomegalovirus infection. ( 28476306 )
2017
21
Severe neonatal cytomegalovirus infection: about a case. ( 28904689 )
2017
22
Prediction of Congenital Cytomegalovirus Infection in High-Risk Pregnant Women. ( 27986675 )
2017
23
CD4(+)CD28(null) T Cells are related to previous cytomegalovirus infection but not to accelerated atherosclerosis in ANCA-associated vasculitis. ( 28084533 )
2017
24
Cytomegalovirus infection: the neurodevelopmental peptide signatures. ( 28875854 )
2017
25
Quantification of Active and Latent Form of Human Cytomegalovirus Infection in Umbilical Cord Blood Donors by Real-Time PCR. ( 28924462 )
2017
26
The Serological Evidence of Cytomegalovirus Infection as a Potent Aetiological Factor for Cleft Lip/Palate, Mental Retardation and Deafness. ( 28764293 )
2017
27
Magnitude of the Cytomegalovirus infection among pregnant women attending antenatal clinics in the city of Mwanza, Tanzania. ( 28931421 )
2017
28
Pulmonary Calcification in a Congenital Cytomegalovirus Infection. ( 28807358 )
2017
29
High prevalence of cytomegalovirus infection in surgical intestinal specimens from infants with necrotizing enterocolitis and spontaneous intestinal perforation: A retrospective observational study. ( 28633098 )
2017
30
Public Health Impact of Congenital Toxoplasmosis and Cytomegalovirus Infection in Belgium, 2013: A Systematic Review and Data Synthesis. ( 28605518 )
2017
31
Clinical evaluation of the new Roche platform of serological and molecular cytomegalovirus-specific assays in the diagnosis and prognosis of congenital cytomegalovirus infection. ( 28801056 )
2017
32
Symptomatic Congenital Cytomegalovirus Infection in Children of Seropositive Women. ( 28649563 )
2017
33
Cytokine gene polymorphism associations with congenital cytomegalovirus infection and sensorineural hearing loss. ( 28501927 )
2017
34
Cytomegalovirus infection after kidney transplantation and long-term graft loss. ( 28946964 )
2017
35
A case of cytomegalovirus infection with splenic infarction and an esophageal ulcer in an immunocompetent adult. ( 28679983 )
2017
36
The role of immunoglobulin prophylaxis for prevention of cytomegalovirus infection in pediatric hematopoietic stem cell transplantation recipients. ( 28087884 )
2017
37
Adjuvant Peptide Pulsed Dendritic Cell Vaccination in Addition to T Cell Adoptive Immunotherapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplantation Recipients. ( 28864137 )
2017
38
Treatment of immune thrombocytopenic purpura associated with cytomegalovirus infection in a child with pre-B cell acute lymphoblastic leukaemia after central nervous system relapse. ( 28947425 )
2017
39
Intrauterine fetal death due to congenital cytomegalovirus infection. ( 28606416 )
2017
40
Association of TLR3 L412F Polymorphism with Cytomegalovirus Infection in Children. ( 28046022 )
2017
41
RMND1-Related Leukoencephalopathy With Temporal Lobe Cysts and Hearing Loss-Another Mendelian Mimicker of Congenital Cytomegalovirus Infection. ( 27843092 )
2017
42
Acute macular neuroretinopathy associated with subclinical cytomegalovirus infection. ( 27444308 )
2017
43
Congenital Cytomegalovirus Infection: Child Development, Quality of Life and Impact on Daily Life. ( 28650934 )
2017
44
Neonatal screening parameters in infants with congenital Cytomegalovirus infection. ( 28847685 )
2017
45
High Seroprevalence of CMV Among Women of Childbearing Age Implicates High Burden of Congenital Cytomegalovirus Infection in Poland. ( 28735326 )
2017
46
Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey. ( 28859257 )
2017
47
T and B Cell Markers in Dried Blood Spots of Neonates with Congenital Cytomegalovirus Infection: B Cell Numbers at Birth Are Associated with Long-Term Outcomes. ( 27903736 )
2017
48
Asymptomatic portal vein thrombosis associated to acute cytomegalovirus infection in an immunocompetent patient. ( 28919211 )
2017
49
Preventing Congenital Cytomegalovirus Infection. ( 28825308 )
2017
50
Human cytomegalovirus infection contributes to glioma disease progression via upregulating endocan expression. ( 27474433 )
2016

Variations for Cytomegalovirus Infection

Expression for Cytomegalovirus Infection

Search GEO for disease gene expression data for Cytomegalovirus Infection.

Pathways for Cytomegalovirus Infection

Pathways related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show top 50) (show all 71)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14 CCL5 CXCL8 HLA-G ICAM1 IFNG IL10
2
Show member pathways
13.67 CCL5 CXCL8 IFNG IL10 IL2RA IL6
3
Show member pathways
13.57 CCL5 CXCL8 ICAM1 IFNG IL10 IL2RA
4
Show member pathways
13.42 CCL5 CXCL8 IL10 IL2RA IL6 MTOR
5
Show member pathways
13.31 CCL5 CXCL8 HLA-G ICAM1 IFNG IL10
6
Show member pathways
12.93 CCL5 CXCL8 IFNG IL10 IL6 TNF
7
Show member pathways
12.83 CCL5 CXCL8 HLA-G ICAM1 IFNG IL2RA
8
Show member pathways
12.76 CCL5 CXCL8 IFNG IL6 TNF
9
Show member pathways
12.76 CXCL8 HLA-G ICAM1 IFNG IL10 IL2RA
10
Show member pathways
12.66 IFNG IL10 IL2RA IL6 MTOR TNF
11 12.59 CCL5 IFNG IL10 IL2RA RAG1 TNF
12
Show member pathways
12.57 HLA-G ICAM1 IFNG KIR3DL1 TNF
13
Show member pathways
12.54 HLA-G ICAM1 IFNG VCAM1
14 12.49 HLA-G ICAM1 IL2RA IL6 TNF VCAM1
15
Show member pathways
12.45 IFNG IL10 IL6 TNF
16
Show member pathways
12.44 ICAM1 IL10 MTOR VCAM1
17
Show member pathways
12.36 CXCL8 IFNG IL6 TNF
18 12.33 HLA-G ICAM1 IFNG IL10
19
Show member pathways
12.31 CXCL8 IFNG IL6 TNF
20
Show member pathways
12.28 IFNG IL10 IL2RA IL6 MTOR
21 12.27 IFNG IL10 IL6 TNF
22
Show member pathways
12.23 CXCL8 IFNG IL6 TNF
23 12.22 CXCL8 IL10 IL6 TNF
24
Show member pathways
12.21 CXCL8 HLA-G IFNG IL10 IL6 TNF
25 12.17 ICAM1 IFNG SELE TNF VCAM1
26 12.16 HLA-G ICAM1 SELE VCAM1
27 12.15 HLA-G ICAM1 KIR3DL1 KLRB1 VCAM1
28 12.09 CXCL8 ICAM1 IFNG IL6 TNF
29 12.06 IFNG IL10 IL2RA IL6 KLRB1 TNF
30 12.03 CXCL8 ICAM1 IL10 IL6 TNF VCAM1
31 12.02 CXCL8 IFNG IL6 MTOR
32
Show member pathways
12.02 IFNG IL10 IL6 TNF
33 11.99 CCL5 ICAM1 IL6 SELE TNF VCAM1
34 11.98 IFNG IL10 IL2RA IL6 MTOR
35 11.97 CXCL8 IFNG IL10 IL6 TNF
36
Show member pathways
11.96 IL6 MTOR TNF
37 11.96 CXCL8 ICAM1 TNF VCAM1
38 11.91 IFNG IL6 MTOR
39 11.91 CXCL8 ICAM1 IL6 SELE TNF VCAM1
40 11.9 IL2RA IL6 TNF
41 11.89 CXCL8 ICAM1 IFNG IL6 SELE
42
Show member pathways
11.88 CXCL8 ICAM1 IL6
43 11.87 IFNG IL10 IL2RA KLRB1 TNF
44 11.85 CXCL8 IFNG IL6
45
Show member pathways
11.85 CXCL8 IFNG IL2RA TNF
46 11.85 CXCL8 IL10 IL6 TNF
47 11.84 IFNG IL10 IL6 TNF
48 11.84 CCL5 CXCL8 ICAM1 IFNG IL6 TNF
49 11.75 CCL5 CXCL8 IL6 TNF
50
Show member pathways
11.69 IFNG IL2RA TNF

GO Terms for Cytomegalovirus Infection

Cellular components related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 CCL5 CXCL8 ICAM1 IFNG IL10 IL6
2 external side of plasma membrane GO:0009897 9.1 ICAM1 IFNG IL2RA IL6 TNF VCAM1

Biological processes related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
id Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.98 CCL5 CXCL8 IL10 IL2RA IL6 SELE
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.96 CCL5 ICAM1 IL6 TNF
3 aging GO:0007568 9.94 GJB2 IL10 IL6 VCAM1
4 positive regulation of protein kinase B signaling GO:0051897 9.88 IL6 MTOR TNF
5 regulation of immune response GO:0050776 9.88 HLA-G ICAM1 IFNG KIR3DL1 KLRB1 VCAM1
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.87 ICAM1 IL6 MTOR
7 response to glucocorticoid GO:0051384 9.86 IL10 IL6 TNF
8 regulation of insulin secretion GO:0050796 9.86 CCL5 IFNG TNF
9 B cell differentiation GO:0030183 9.85 IL10 RAG1 VCAM1
10 cellular response to interleukin-1 GO:0071347 9.85 CCL5 CXCL8 ICAM1 IL6
11 cellular response to tumor necrosis factor GO:0071356 9.85 CCL5 CXCL8 ICAM1 IL6 VCAM1
12 response to lipopolysaccharide GO:0032496 9.85 GJB2 ICAM1 IL10 IL6 SELE VCAM1
13 neutrophil chemotaxis GO:0030593 9.84 CCL5 CXCL8 IFNG
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.84 CCL5 IFNG IL6
15 interferon-gamma-mediated signaling pathway GO:0060333 9.84 HLA-G ICAM1 IFNG VCAM1
16 humoral immune response GO:0006959 9.83 IFNG IL6 TNF
17 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.81 ICAM1 SELE VCAM1
18 response to insulin GO:0032868 9.81 ICAM1 IL10 IL6 MTOR
19 positive regulation of cell adhesion GO:0045785 9.8 CCL5 IFNG TNF
20 negative regulation of T cell proliferation GO:0042130 9.79 HLA-G IL10 IL2RA
21 positive regulation of smooth muscle cell proliferation GO:0048661 9.78 CCL5 IL6 MTOR TNF
22 cellular response to dexamethasone stimulus GO:0071549 9.77 GJB2 ICAM1 IL6
23 response to amino acid GO:0043200 9.76 ICAM1 IL6 MTOR
24 defense response to protozoan GO:0042832 9.74 IFNG IL10 IL6
25 negative regulation of growth of symbiont in host GO:0044130 9.73 IFNG IL10 TNF
26 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.72 IFNG TNF
27 regulation of osteoclast differentiation GO:0045670 9.72 MTOR TNF
28 negative regulation of immune response GO:0050777 9.71 HLA-G IL2RA
29 cellular response to hepatocyte growth factor stimulus GO:0035729 9.71 IL10 IL6
30 acute inflammatory response GO:0002526 9.71 IL6 VCAM1
31 response to molecule of bacterial origin GO:0002237 9.71 CXCL8 IL10
32 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.7 IL10 TNF
33 negative regulation of G-protein coupled receptor protein signaling pathway GO:0045744 9.7 CCL5 CXCL8
34 positive regulation of protein import into nucleus, translocation GO:0033160 9.7 IFNG IL6
35 leukocyte tethering or rolling GO:0050901 9.7 SELE TNF VCAM1
36 positive regulation of chemokine biosynthetic process GO:0045080 9.69 IFNG TNF
37 negative regulation of lipid storage GO:0010888 9.69 IL6 TNF
38 neutrophil activation GO:0042119 9.69 CCL5 CXCL8
39 endothelial cell apoptotic process GO:0072577 9.68 IL10 TNF
40 negative regulation of T cell apoptotic process GO:0070233 9.67 CCL5 RAG1
41 positive regulation of MHC class II biosynthetic process GO:0045348 9.67 IFNG IL10
42 cellular response to nutrient levels GO:0031669 9.67 ICAM1 IL6 MTOR
43 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.65 ICAM1 TNF
44 negative regulation of cytokine secretion involved in immune response GO:0002740 9.65 IL10 TNF
45 positive regulation of T cell proliferation GO:0042102 9.65 CCL5 IFNG IL2RA IL6 VCAM1
46 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.64 IL6 TNF
47 membrane to membrane docking GO:0022614 9.63 ICAM1 VCAM1
48 cellular response to lipopolysaccharide GO:0071222 9.63 CXCL8 ICAM1 IFNG IL10 IL6 TNF
49 leukocyte cell-cell adhesion GO:0007159 9.62 CCL5 ICAM1 SELE VCAM1
50 receptor biosynthetic process GO:0032800 9.61 IL10 TNF

Molecular functions related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.1 CCL5 CXCL8 IFNG IL10 IL6 TNF

Sources for Cytomegalovirus Infection

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....